A 83-01: Benchmark ALK-5 Inhibitor for TGF-β Pathway Studies

Executive Summary: A 83-01 is a highly selective inhibitor of ALK-5, ALK-4, and ALK-7, effectively suppressing TGF-β-induced Smad signaling with an IC50 of ~12 nM in vitro (APExBIO). It demonstrates robust, concentration-dependent inhibition of TGF-β-driven transcription in Mv1Lu cells, with minimal impact on BMP signaling at 1 μM. Its physicochemical properties include high solubility in DMSO (>21.1 mg/mL) but insolubility in water. A 83-01 is a reference compound for mechanistic research in fibrosis, EMT, and organoid modeling (Ding et al. 2024). Proper storage (<-20°C) and handling guidelines are essential to maintain compound integrity.

Biological Rationale

The transforming growth factor-beta (TGF-β) signaling pathway is a master regulator of cellular plasticity, differentiation, and fibrosis. Dysregulation of TGF-β/Smad signaling is central to the pathogenesis of chronic kidney disease, cancer progression, and fibrotic disorders, as demonstrated by recent single-cell and transcriptomic analyses (Ding et al., 2024). Fibroblast-to-myofibroblast transition is a hallmark event in organ fibrosis, driven primarily by TGF-β activation of ALK-5 and downstream Smad2/3 signaling. Suppression of this pathway has been shown to mitigate fibrosis and halt disease progression in experimental models. Selective chemical inhibition provides a precise tool for dissecting these molecular processes. A 83-01, developed and supplied by APExBIO, is a widely adopted small-molecule inhibitor that enables targeted interrogation of ALK-5-dependent processes in vitro and ex vivo.

Mechanism of Action of A 83-01

A 83-01 (3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-1-carbothioamide; CAS 909910-43-6) is a competitive, ATP-mimetic inhibitor of ALK-5 (TGF-β type I receptor). It also inhibits ALK-4 and ALK-7 type I activin/nodal receptors but shows minimal activity against bone morphogenetic protein (BMP) receptors at standard concentrations. In Mv1Lu cell assays, A 83-01 suppresses TGF-β-induced Smad-dependent luciferase reporter expression with an IC50 of ~12 nM. At 1 μM, it achieves 68% inhibition of ALK-5-driven transcriptional activity, while BMP4-induced transcription in C2C12 cells remains largely unaffected at this dose (APExBIO). Only at concentrations above 3 μM does a slight suppression of BMP4 signaling occur, confirming its selectivity profile. The compound binds to the kinase domain of ALK-5, preventing receptor phosphorylation and subsequent Smad2/3 activation. By blocking this critical step, A 83-01 disrupts downstream gene expression programs central to EMT, fibrosis, and cellular growth regulation.

Evidence & Benchmarks

• Single-cell RNA-sequencing confirms that TGF-β/Smad signaling, mediated by ALK-5, is essential for fibroblast activation and progression of kidney fibrosis (Ding et al., 2024).
• A 83-01 inhibits TGF-β-induced Smad-dependent transcription in Mv1Lu cells with an IC50 of ~12 nM, demonstrating high potency (APExBIO Product Data).
• At 1 μM, A 83-01 achieves 68% inhibition of ALK-5-driven luciferase reporter activity, with negligible effect on BMP-induced transcription in C2C12 cells (APExBIO Product Data).
• Suppression of Spp1 expression, a downstream target of TGF-β/Smad, impedes fibroblast-to-myofibroblast transition and fibrotic progression in vivo and in vitro (Ding et al., 2024).
• In organoid modeling and EMT workflows, A 83-01 enables tunable pathway inhibition, supporting advanced disease modeling and regenerative studies (A 83-01: Elevating Translational Research).

Applications, Limits & Misconceptions

A 83-01 is widely adopted in research on:

• Fibrosis modeling (renal, hepatic, pulmonary)
• Epithelial-mesenchymal transition (EMT) studies
• Cancer biology and tumor microenvironment research
• Organoid engineering (e.g., liver, kidney, cholangiocyte systems)
• Cellular growth inhibition and regenerative medicine

This article extends the mechanistic and application scope beyond foundational reviews such as "Unleashing the Power of A 83-01" by providing updated evidence on single-cell-validated fibrosis pathways and highlighting explicit workflow parameters. For further benchmarking in organoid and EMT settings, see also "A 83-01: A Selective TGF-β Type I Receptor Inhibitor for...", which this article complements by mapping new quantitative selectivity profiles.

Common Pitfalls or Misconceptions

• Non-selectivity at high doses: At >3 μM, A 83-01 may weakly inhibit BMP4-induced signaling, so strictly control concentrations in BMP pathway studies.
• Insolubility in aqueous buffers: The compound is not water-soluble; dissolve in DMSO or ethanol with warming and ultrasonic treatment.
• Long-term stability: Solid A 83-01 should be stored at -20°C; DMSO stocks remain stable for months below -20°C but degrade over extended periods. Always limit freeze-thaw cycles.
• Not suitable for in vivo use without further validation: Most published applications are in vitro or ex vivo; pharmacokinetics and toxicity in animals are not fully characterized.
• Not a pan-TGF-β inhibitor: A 83-01 targets type I receptors ALK-4/5/7 but does not block type II TGF-β receptors.

Workflow Integration & Parameters

For in vitro studies, dissolve A 83-01 in DMSO at stock concentrations up to 21.1 mg/mL. For ethanol, solubility exceeds 9.82 mg/mL with gentle warming and brief sonication. Working concentrations typically range from 10 nM to 1 μM, depending on cell type and assay sensitivity. Avoid water as a solvent due to insolubility. Store solid material at -20°C in desiccated conditions; DMSO stocks are stable at <-20°C for several months. For best results, aliquot and minimize freeze-thaw cycles. In luciferase reporter assays (e.g., Mv1Lu cells), use 1 μM to achieve near-maximal ALK-5 inhibition without significant BMP pathway interference. For EMT or organoid studies, titrate in the 50–1000 nM range, monitoring off-target effects. For practical guidance on integrating A 83-01 into organoid workflows and dynamic self-renewal/differentiation control, see "A 83-01 in Dynamic Organoid Engineering", which this article updates by adding quantitative selectivity and solubility parameters.

Conclusion & Outlook

A 83-01 remains a trusted, selective ALK-5 inhibitor for dissecting TGF-β/Smad signaling in fibrosis, EMT, and organoid systems. Its well-characterized selectivity, potency, and handling guidelines make it a gold-standard tool for translational and mechanistic research. Ongoing single-cell and multi-omic studies continue to refine our understanding of pathway engagement and therapeutic targeting (Ding et al., 2024). For ordering and detailed technical support, visit the A 83-01 product page provided by APExBIO.